Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non–small cell lung cancer negative for EGFR mutation and ALK fusion

Objectives Immune-checkpoint inhibitors (ICIs) are now an established therapeutic option for advanced non–small cell lung cancer (NSCLC). It has remained unclear, however, whether cytotoxic chemotherapy affects the immune microenvironment in NSCLC wild type for EGFR and ALK. Materials and methods We retrospectively evaluated changes in programmed cell death 1–ligand 1 (PD-L1) expression, tumor mutation burden (TMB), and CD8+ tumor-infiltrating...